<DOC>
	<DOC>NCT00071747</DOC>
	<brief_summary>The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.</brief_summary>
	<brief_title>Clinical Study Of Schizophrenia in Both Men and Women</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Inclusion criteria: If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception. Diagnosis of Schizophrenia Patients must be taking clozapine monotherapy or other atypical antipsychotic at least 3 months prior to this study. Exclusion criteria: Patients who are currently taking or have taken antidepressant medication in the last month prior. Patients who are or have been suicidal or homicidal in the last 6 months. Patients with a history of autistic disorder or another pervasive developmental disorder Patients whose condition is due to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>lamotrigine</keyword>
</DOC>